Morgan Stanley Cuts Bicycle Therapeutics (NASDAQ:BCYC) Price Target to $45.00

Bicycle Therapeutics (NASDAQ:BCYCGet Rating) had its target price trimmed by Morgan Stanley from $60.00 to $45.00 in a report published on Monday, Stock Target Advisor reports. They currently have an equal weight rating on the stock.

Several other brokerages have also weighed in on BCYC. JMP Securities reaffirmed a buy rating and issued a $70.00 target price on shares of Bicycle Therapeutics in a research report on Thursday, September 8th. Barclays started coverage on Bicycle Therapeutics in a research report on Thursday, July 28th. They issued an overweight rating and a $30.00 target price on the stock. SVB Leerink upped their target price on Bicycle Therapeutics from $48.00 to $50.00 and gave the stock an outperform rating in a research report on Monday, August 22nd. HC Wainwright lowered their price objective on Bicycle Therapeutics from $65.00 to $57.00 and set a buy rating on the stock in a report on Friday, August 5th. Finally, Canaccord Genuity Group reissued a buy rating and set a $60.00 price objective on shares of Bicycle Therapeutics in a report on Wednesday, July 6th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $55.92.

Bicycle Therapeutics Stock Down 0.4 %

NASDAQ:BCYC opened at $24.98 on Monday. The firm has a market capitalization of $741.31 million, a price-to-earnings ratio of -8.19 and a beta of 0.71. Bicycle Therapeutics has a 1-year low of $12.08 and a 1-year high of $62.08. The company has a current ratio of 9.88, a quick ratio of 9.88 and a debt-to-equity ratio of 0.10. The business’s fifty day moving average price is $23.95 and its 200 day moving average price is $25.91.

Bicycle Therapeutics (NASDAQ:BCYCGet Rating) last issued its earnings results on Thursday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Bicycle Therapeutics had a negative return on equity of 30.07% and a negative net margin of 533.03%. On average, sell-side analysts forecast that Bicycle Therapeutics will post -3.8 earnings per share for the current fiscal year.

Institutional Trading of Bicycle Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Prospera Financial Services Inc bought a new stake in Bicycle Therapeutics during the 1st quarter valued at approximately $88,000. Quantbot Technologies LP bought a new stake in shares of Bicycle Therapeutics in the 2nd quarter worth approximately $60,000. Claro Advisors LLC bought a new stake in shares of Bicycle Therapeutics in the 4th quarter worth approximately $221,000. Twelve Points Wealth Management LLC bought a new stake in shares of Bicycle Therapeutics in the 4th quarter worth approximately $432,000. Finally, Engineers Gate Manager LP bought a new stake in shares of Bicycle Therapeutics in the 1st quarter worth approximately $341,000. Institutional investors own 76.45% of the company’s stock.

Bicycle Therapeutics Company Profile

(Get Rating)

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.

Read More

Analyst Recommendations for Bicycle Therapeutics (NASDAQ:BCYC)

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.